Tyck till om SwePub Sök här!
onr:"swepub:oai:DiVA.org:oru-6999"
Search: onr:"swepub:oai:DiVA.org:oru-6999" > Treatment of primar...
- 1 of 1
- Previous record
- Next record
- To hitlist
- Sorbe, BengtÖrebro universitet,Hälsoakademin,Department of Gynecological Oncology, University Hospital, Örebro, Sweden, Department of Gynecological Oncology, University Hospital, SE-701 85 Örebro, Sweden (author)
Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up
- Article/chapterEnglish2008
Publisher, publication year, extent ...
- Blackwell Publishing Ltd,2008
- printrdacarrier
Numbers
- LIBRIS-ID:oai:DiVA.org:oru-6999
- https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-6999URI
- https://doi.org/10.1111/j.1525-1438.2007.01094.xDOI
- https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-46046URI
- https://lup.lub.lu.se/record/1254937URI
- https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-45900URI
Supplementary language notes
- Language:English
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- There is no generally accepted standard chemotherapy in treatment of advanced and recurrent endometrial carcinoma. Cisplatin and doxorubicin with or without cyclophosphamide are widely used. Response rates have improved with combination chemotherapy compared with single-agent therapy. A platinum analog seems to be an important part of the chemotherapy regimen. Since few patients are cured from their disease and since the duration of response is short, further improvement of this therapy is warranted. During the past years, the taxanes (paclitaxel) are being added to prior evaluated regimens and not only improved response rates are reported but also increased toxicity is observed. In a prospective, phase II, multicenter study, carboplatin (area under the curve = 5) and paclitaxel (175 mg/m(2)) were evaluated in treatment of primary advanced and recurrent endometrial carcinoma. In total, 66 patients were recruited during the years 2000-2004. Eighteen primary advanced tumors and 48 recurrences were treated. All histologic types and tumor grades were allowed. The median follow-up was 57 months (range 37-69 months). The overall response rate was 67% (95% CI 55-78). The complete response rate was 29% and the partial response rate 38%. Primary advanced and recurrent tumors as well as endometrioid and nonendometrioid tumors showed similar response rates. The median response duration was 14 months. The 1- and 3-year survival rates were 82% and 33%, respectively. The main toxicities were hematologic and neurologic (sensory neuropathy). The response rates were encouraging, superior to prior platinum-containing regimens, but response duration and the long-term survival rate were still short. The neurologic toxicity was frequent and was a substantial problem in this series of patients. Further research is highly needed to improve the treatment of advanced and recurrent endometrial cancer.
Subject headings and genre
- MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Cancer och onkologi hsv//swe
- MEDICAL AND HEALTH SCIENCES Clinical Medicine Cancer and Oncology hsv//eng
- MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Reproduktionsmedicin och gynekologi hsv//swe
- MEDICAL AND HEALTH SCIENCES Clinical Medicine Obstetrics, Gynaecology and Reproductive Medicine hsv//eng
- Taxol
- carboplatin
- endometrial cancer
- MEDICINE
- MEDICIN
- Oncology
- Onkologi
- Obstetrics and gynaecology
- Obstetrik och gynekologi
- Oncology
- onkologi
- chemotherapy
- carboplatin
- paclitaxel
- endometrial cancer
Added entries (persons, corporate bodies, meetings, titles ...)
- Andersson, HDepartment of Gynecological Oncology, University Hospital, Gothenburg, Sweden (author)
- Boman, KarinUmeå universitet,Onkologi,Department of Gynecological Oncology, University Hospital, Umeå, Sweden(Swepub:umu)kabo0010 (author)
- Rosenberg, PerÖstergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Onkologi,Onkologiska kliniken US(Swepub:liu)perro95 (author)
- Kalling, MårtenLund University,Lunds universitet,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Department of Gynecologic Oncology, University Hospital, Lund, Sweden(Swepub:lu)extLU-138 (author)
- Örebro universitetHälsoakademin (creator_code:org_t)
Related titles
- In:International Journal of Gynecological Cancer: Blackwell Publishing Ltd18:4, s. 803-8081048-891X1525-1438
Internet link
- http://dx.doi.org/10.1111/j.1525-1438.2007.01094.xFULLTEXT
- https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-6999
- https://doi.org/10.1111/j.1525-1438.2007.01094.x
- https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-46046
- https://lup.lub.lu.se/record/1254937
- https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-45900
Find in a library
- International Journal of Gynecological Cancer (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Sorbe, Bengt
- Andersson, H
- Boman, Karin
- Rosenberg, Per
- Kalling, Mårten
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Obstetrics Gynae ...
- Articles in the publication
- International Jo ...
- By the university
- Örebro University
- Umeå University
- Lund University
- Linköping University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
